The authors would like to acknowledge Elizabeth Mansfield, PhD, for providing technical advice.
DanceyJDobbinKGroshenS. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res2010;16:1745–1755.
IOM (Institute of Medicine). Policy issues in the development of personalized medicine in oncology: workshop summary. Washington, DC: The National Academies Press; 2010.
The Medical Device Amendments of 1976. Public L No. 94-295 90 Stat 539.
US Department of Health and Human Services. In vitro diagnostic products for human use. 21 CFR §809.3. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=809.3. Revised April 1 2011.
Draft guidance for industry clinical laboratories and FDA staff: in vitro diagnostic multivariate index assays. US Food and Drug Administration Web site. Available at: www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.htm. Accessed August 11 2011.
Medical devices; classification/reclassification; restricted devices; analyte specific reagents—FDA. Final rule. Fed Regist1997;62:62243–62249.
Draft guidance for industry and Food and Drug Administration staff – in vitro companion diagnostic devices (July142011). US Food and Drug Administration Web site. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm.
FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. US Food and Drug Administration Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm. Accessed August 24 2011.
FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. US Food and Drug Administration Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm. Accessed August 27 2011.
TeutschSMBradleyLAPalomakiGE. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med2009;11:3–14.
Technology Evaluation Center Criteria. BlueCross BlueShield Association Web site. Available at: http://www.bcbs.com/blueresources/tec/tec-criteria.html. Accessed September 19 2011.
BlankPRMochHSzucsTD. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res2011;17:6338–6346.
ShiroiwaTMotooYTsutaniK. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther2010;14:375–384.
Federal Register / Vol. 76 No. 38 / Friday February 25 2011/Notices. Available at: http://edocket.access.gpo.gov/2011/pdf/2011-4295.pdf. Accessed November 21 2011.
CPT Editorial Panel: Molecular Pathology Coding Workgroup. American Medical Asscociation Web site. Available at: http://www.ama-assn.org/resources/doc/cpt/molecular-pathology-coding-workgroup.pdf. Accessed September 19 2011.
National Coverage Determination (NCD) for Pharmacogenomic Testing for Warfarin Response. Centers for Medicare & Medicaid Services Web site. Available at: https://www.cms.gov/medicare-coverage-database/details/ncd-details. Accessed September 19 2011.